<DOC>
	<DOCNO>NCT00036140</DOCNO>
	<brief_summary>The primary goal study determine best dose investigational drug give patient multiple myeloma evaluate investigational drug 's effectiveness treatment multiple myeloma .</brief_summary>
	<brief_title>Study Safety Efficacy Investigational Drug Adult Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Other specific inclusion/exclusion criterion may apply . In order determine eligibility , examination investigator necessary . Eligible patient must least 18 year age diagnosis multiple myeloma include elevated Mblood/urine protein tumor evaluate doctor investigational drug 's treatment . The patient 's multiple myeloma must get bad during/after previous chemotherapy give . Any sideeffects prior chemotherapy must subside Blood urine test must show adequate bone marrow , liver , kidney function . Any following exclude patient study participation : indolent smolder myeloma localize plasmacytoma hyperviscosity syndrome irradiation 25 % bone marrow prior high dose chemotherapy bone marrow stem cell support current participation clinical trial pregnant breastfeeding woman know HIVpositive AIDSrelated illness patient plan radiation therapy surgery would interrupt study therapy next 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Pharmacia</keyword>
</DOC>